Reclaiming Asia’s Genomic Destiny
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
Address: 5F, DaeHan Bldg 201-6, Guui-Dong, Kwangjin-Gu Seoul,Republic of Korea
Tel: +82 2 456 3043
KRPIA represents Republic of Korean Research-based Pharmaceutical Industry Association. KRPIA is the association of research-based companies which deliver innovative new medicines to the market through incessant research endeavors. KRPIA was established in March 1999, consisting of 24 multinational research-based pharmaceutical companies operating in Republic of Korea. At present, KRPIA has 28 member companies which are taking the lead in the world’s pharmaceutical market. KRPIA believes ‘New Medicines, New Hope’ so it is devoted to providing new innovative drugs in Republic of Korea and disseminating pharmaceutical-related information. KRPIA members have the best possible conditions to research, develop, market and inform about their pharmaceuticals, thus ensuring broad and fast access for patients to the best medical treatment. The value of research based medicines for the Republic of Korean society is visible and recognized in a health system with the patient as priority. The Republic of Korean Research-based Pharmaceutical Industry Association is perceived as a responsible partner that makes a valuable contribution to society.Mision: Promote the development and prompt introduction of innovative new pharmaceuticals Enhance the ethical standards of the pharmaceutical industry Strengthen the pharmaceutical industry’s contribution to the advancement of public health Effectively disseminate pharmaceutical-related information and contribute to medical treatment for patients and public health promotion
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
Dr Jeong-Sun Seo, chairman of Macrogen & president of the Korea Biotechnology Industry Organization (KoreaBIO), explains the basis for Korea’s success in combating the spread of COVID-19, casts light on…
Gencurix was the first Asian company to develop a prognostic diagnostic test for breast cancer. Its CEO, Dr Sangrae Cho, discusses the importance of creating a test tailored to Asian…
Yeul-Hong Kim, Director of K-MASTER details the project’s success in creating a shared database of genomic data for Korean oncology professionals. Kim also explains the importance of collaboration with Big…
Korean biosimilar firm Celltrion’s USD 266 million acquisition of Japanese outfit Takeda assets in the Asia-Pacific region marks a significant moment in Celltrion’s international expansion as well as yet another…
Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in several global M&A deals in the past year with the end goal of…
Genome & Company, with a market cap of USD 280 million, is the highest valued microbiome company worldwide. Dr Jisoo Pae, its co-founder and CEO, sat down with PharmaBoardroom to…
After failing to attain reimbursement for its Amyotrophic Lateral Sclerosis (ALS) treatment NEURONATA-R® in Korea, Corestem has its sights set on the US market and an Investigational New Drug (IND)…
Kyung Suk Kim, CEO of Corestem, the first company to receive approval for a stem cell therapy for Amyotrophic Lateral Sclerosis (ALS) in Korea, recounts the firm’s main achievements since…
With over 30 years of experience in public office working in public health and pharmaceutical policy, food and drug safety regulations, national health and welfare policy, and overseas missions as…
Dr Bae Byuongjun, president of the Korea National Enterprise for Clinical Trials (KoNECT), outlines why Korea stands out in the APAC region as a top clinical trial destination, how clinical…
Founder, CEO and CTO Dr Chae-Ok Yun introduces GeneMedicine, a pioneer of the oncolytic virus approach in gene therapy. Dr Yun outlines the significance of a recent capital injection, ongoing…
See our Cookie Privacy Policy Here
